Logo image of COV.PA

COVIVIO (COV.PA) Stock Fundamental Analysis

EPA:COV - Euronext Paris - Matif - FR0000064578 - REIT - Currency: EUR

49.62  +0.32 (+0.65%)

Fundamental Rating

4

COV gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 42 industry peers in the Diversified REITs industry. While COV is still in line with the averages on profitability rating, there are concerns on its financial health. COV has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

COV had positive earnings in the past year.
COV had a positive operating cash flow in the past year.
Of the past 5 years COV 4 years were profitable.
COV had a positive operating cash flow in each of the past 5 years.
COV.PA Yearly Net Income VS EBIT VS OCF VS FCFCOV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B -1B

1.2 Ratios

With a Return On Assets value of 0.27%, COV is not doing good in the industry: 66.67% of the companies in the same industry are doing better.
COV has a worse Return On Equity (0.83%) than 66.67% of its industry peers.
Looking at the Return On Invested Capital, with a value of 3.14%, COV is in line with its industry, outperforming 42.86% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for COV is in line with the industry average of 3.74%.
The 3 year average ROIC (2.97%) for COV is below the current ROIC(3.14%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.27%
ROE 0.83%
ROIC 3.14%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
COV.PA Yearly ROA, ROE, ROICCOV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10

1.3 Margins

The Profit Margin of COV (5.23%) is worse than 66.67% of its industry peers.
COV's Profit Margin has declined in the last couple of years.
COV's Operating Margin of 61.20% is on the low side compared to the rest of the industry. COV is outperformed by 66.67% of its industry peers.
COV's Operating Margin has been stable in the last couple of years.
COV has a Gross Margin (76.74%) which is in line with its industry peers.
COV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 61.2%
PM (TTM) 5.23%
GM 76.74%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
COV.PA Yearly Profit, Operating, Gross MarginsCOV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), COV is destroying value.
The number of shares outstanding for COV has been increased compared to 1 year ago.
The number of shares outstanding for COV has been increased compared to 5 years ago.
Compared to 1 year ago, COV has an improved debt to assets ratio.
COV.PA Yearly Shares OutstandingCOV.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COV.PA Yearly Total Debt VS Total AssetsCOV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

COV has an Altman-Z score of 0.55. This is a bad value and indicates that COV is not financially healthy and even has some risk of bankruptcy.
COV has a Altman-Z score of 0.55. This is amonst the worse of the industry: COV underperforms 80.95% of its industry peers.
The Debt to FCF ratio of COV is 27.72, which is on the high side as it means it would take COV, 27.72 years of fcf income to pay off all of its debts.
COV has a Debt to FCF ratio of 27.72. This is in the lower half of the industry: COV underperforms 71.43% of its industry peers.
A Debt/Equity ratio of 1.14 is on the high side and indicates that COV has dependencies on debt financing.
The Debt to Equity ratio of COV (1.14) is worse than 80.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF 27.72
Altman-Z 0.55
ROIC/WACC0.55
WACC5.69%
COV.PA Yearly LT Debt VS Equity VS FCFCOV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

A Current Ratio of 0.96 indicates that COV may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.96, COV is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
A Quick Ratio of 0.85 indicates that COV may have some problems paying its short term obligations.
COV's Quick ratio of 0.85 is fine compared to the rest of the industry. COV outperforms 71.43% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.85
COV.PA Yearly Current Assets VS Current LiabilitesCOV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

5

3. Growth

3.1 Past

COV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.00%.
Measured over the past years, COV shows a decrease in Earnings Per Share. The EPS has been decreasing by -3.39% on average per year.
COV shows a strong growth in Revenue. In the last year, the Revenue has grown by 22.79%.
The Revenue has been growing slightly by 1.17% on average over the past years.
EPS 1Y (TTM)0%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%5.69%
Revenue 1Y (TTM)22.79%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.62%

3.2 Future

The Earnings Per Share is expected to grow by 1.89% on average over the next years.
Based on estimates for the next years, COV will show a small growth in Revenue. The Revenue will grow by 4.79% on average per year.
EPS Next Y7.5%
EPS Next 2Y1.92%
EPS Next 3Y1.89%
EPS Next 5YN/A
Revenue Next Year-0.42%
Revenue Next 2Y1.71%
Revenue Next 3Y4.79%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
COV.PA Yearly Revenue VS EstimatesCOV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
COV.PA Yearly EPS VS EstimatesCOV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

5

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 11.10, the valuation of COV can be described as very reasonable.
71.43% of the companies in the same industry are more expensive than COV, based on the Price/Earnings ratio.
COV's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.22.
With a Price/Forward Earnings ratio of 10.33, the valuation of COV can be described as very reasonable.
Based on the Price/Forward Earnings ratio, COV is valued a bit cheaper than 61.90% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of COV to the average of the S&P500 Index (20.86), we can say COV is valued rather cheaply.
Industry RankSector Rank
PE 11.1
Fwd PE 10.33
COV.PA Price Earnings VS Forward Price EarningsCOV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

COV's Enterprise Value to EBITDA is on the same level as the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as COV.
Industry RankSector Rank
P/FCF 14.4
EV/EBITDA 17.08
COV.PA Per share dataCOV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
PEG (NY)1.48
PEG (5Y)N/A
EPS Next 2Y1.92%
EPS Next 3Y1.89%

5

5. Dividend

5.1 Amount

COV has a Yearly Dividend Yield of 7.10%, which is a nice return.
COV's Dividend Yield is rather good when compared to the industry average which is at 7.60. COV pays more dividend than 80.95% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.44, COV pays a better dividend.
Industry RankSector Rank
Dividend Yield 7.1%

5.2 History

The dividend of COV decreases each year by -1.54%.
Dividend Growth(5Y)-1.54%
Div Incr Years1
Div Non Decr Years1
COV.PA Yearly Dividends per shareCOV.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 1 2 3 4

5.3 Sustainability

112.19% of the earnings are spent on dividend by COV. This is not a sustainable payout ratio.
DP112.19%
EPS Next 2Y1.92%
EPS Next 3Y1.89%
COV.PA Yearly Income VS Free CF VS DividendCOV.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B
COV.PA Dividend Payout.COV.PA Dividend Payout, showing the Payout Ratio.COV.PA Dividend Payout.PayoutRetained Earnings

COVIVIO

EPA:COV (5/2/2025, 7:00:00 PM)

49.62

+0.32 (+0.65%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)02-19 2025-02-19/amc
Earnings (Next)07-21 2025-07-21
Inst Owners40.89%
Inst Owner ChangeN/A
Ins Owners0.2%
Ins Owner ChangeN/A
Market Cap5.54B
Analysts80
Price Target60.78 (22.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 7.1%
Yearly Dividend0.72
Dividend Growth(5Y)-1.54%
DP112.19%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.2%
PT rev (3m)-2.88%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)1.52%
EPS NY rev (3m)8.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-3.04%
Revenue NY rev (3m)-3.96%
Valuation
Industry RankSector Rank
PE 11.1
Fwd PE 10.33
P/S 4.26
P/FCF 14.4
P/OCF 5.65
P/B 0.67
P/tB 0.7
EV/EBITDA 17.08
EPS(TTM)4.47
EY9.01%
EPS(NY)4.81
Fwd EY9.68%
FCF(TTM)3.45
FCFY6.94%
OCF(TTM)8.78
OCFY17.7%
SpS11.66
BVpS73.72
TBVpS70.63
PEG (NY)1.48
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.27%
ROE 0.83%
ROCE 3.52%
ROIC 3.14%
ROICexc 3.24%
ROICexgc 3.29%
OM 61.2%
PM (TTM) 5.23%
GM 76.74%
FCFM 29.56%
ROA(3y)-1.05%
ROA(5y)0.29%
ROE(3y)-3.48%
ROE(5y)0.76%
ROIC(3y)2.97%
ROIC(5y)2.68%
ROICexc(3y)3.08%
ROICexc(5y)2.79%
ROICexgc(3y)3.11%
ROICexgc(5y)2.81%
ROCE(3y)3.32%
ROCE(5y)3%
ROICexcg growth 3Y12.16%
ROICexcg growth 5Y0.31%
ROICexc growth 3Y11.77%
ROICexc growth 5Y0.14%
OM growth 3Y-1.46%
OM growth 5Y-1.11%
PM growth 3Y-61.53%
PM growth 5Y-38.78%
GM growth 3Y-2.18%
GM growth 5Y-0.89%
F-Score7
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1.14
Debt/FCF 27.72
Debt/EBITDA 10.32
Cap/Depr 519.44%
Cap/Sales 45.79%
Interest Coverage 250
Cash Conversion 107.61%
Profit Quality 564.76%
Current Ratio 0.96
Quick Ratio 0.85
Altman-Z 0.55
F-Score7
WACC5.69%
ROIC/WACC0.55
Cap/Depr(3y)709.28%
Cap/Depr(5y)708.5%
Cap/Sales(3y)50.08%
Cap/Sales(5y)56.76%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y0.91%
EPS 5Y-3.39%
EPS Q2Q%5.69%
EPS Next Y7.5%
EPS Next 2Y1.92%
EPS Next 3Y1.89%
EPS Next 5YN/A
Revenue 1Y (TTM)22.79%
Revenue growth 3Y9.01%
Revenue growth 5Y1.17%
Sales Q2Q%-30.62%
Revenue Next Year-0.42%
Revenue Next 2Y1.71%
Revenue Next 3Y4.79%
Revenue Next 5YN/A
EBIT growth 1Y0.7%
EBIT growth 3Y7.42%
EBIT growth 5Y0.05%
EBIT Next Year9.26%
EBIT Next 3Y7.23%
EBIT Next 5YN/A
FCF growth 1Y-28.86%
FCF growth 3YN/A
FCF growth 5Y31.13%
OCF growth 1Y-4.37%
OCF growth 3Y12.5%
OCF growth 5Y4.86%